MOBIDIAG
Mobidiag Ltd, a Finnish molecular diagnostics for infectious diseases company, today announced it has signed an agreement with Ginolis, expert in assembly automation and high precision liquid handling solutions. Through the implementation of cutting-edge production lines from Ginolis, Mobidiag will be able to answer growing needs in molecular diagnostics for routine use and anticipate the production of upcoming Novodiag® test cartridges.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180304005019/en/
Launched in December 2017, the new Novodiag® solution allows direct analysis of a patient sample placed in a disposable cartridge and delivers comprehensive results in about an hour, compared to days with well-established culture methods. Novodiag® helps make treatment decisions faster and more accurate, avoiding for example the unnecessary use of antibiotics.
“The innovative Novodiag cartridge has been developed at Mobidiag thanks to the combination of multidisciplinary teams and expertise. The cartridge includes state-of-the-art technologies such as qPCR and microarray, bringing with them some specific requirements and constraints. We then needed to successfully automate our processes and move from a small scale production capacity to industrial volumes without compromising quality and costs. Thanks to its cutting-edge modular platforms and expertise in diagnostics processes, we are confident that Ginolis will bring the most relevant solution to support us in our growing activity”, says Tuomas Tenkanen, CEO at Mobidiag.
The manufacturing solution developed for Mobidiag is based on Ginolis’ modular Xanthia automation platform. Its compact and modular design allows for high quality automation within a small footprint, saving valuable space in the clean room environment. In addition to Ginolis’ patented dispensing technology, the line is equipped with laser welding, precision assembly, ultrasonic welding and line confocal imaging (LCI) for quality inspection.
“The demand for molecular diagnostics is on the rise and we are proud to continue our long-standing cooperation with Mobidiag. Both companies share a dedication to innovation and high quality”, says Ginolis CEO Teijo Fabritius. “This line is a testament to the scalability of our flexible modular solutions and ability to integrate the entire manufacturing process on one platform.”
Antibiotic resistance is one of the greatest threats to the world's health. According to the World Health Organization, the number of antibiotic-resistant bacteria grows at an alarming rate worldwide and all efforts should be taken to stop this development. Fast and reliable diagnostics are needed to detect resistance and thereby reduce the use of antibiotics.
With rapid tests and high-capacity production lines, Mobidiag is able to respond to rapidly growing requirements for infection diagnosis, including antibiotic resistance. A Novodiag® cartridge currently under development and planned to be released in mid-2018.
About Novodiag
®
The Novodiag®
solution allows direct analysis of a patient sample placed in a
disposable cartridge and delivers comprehensive results in about an hour.
Combining
qPCR and microarray technologies, Novodiag offers an all in one solution
for on-demand targeted and syndromic testing.
This molecular
diagnostic solution offers an easy to use and cost-efficient method,
with very limited hands-on-time and without the need for much technical
expertise. Novodiag is particularly suitable for low volumes and on
demand testing for clinical laboratories.
Learn more about Novodiag
®
.
About Mobidiag Ltd.
Established in 2000, Mobidiag develops
and commercializes innovative solutions to advance the diagnosis of
infectious diseases and serves the European clinical diagnostics market
since 2008. Mobidiag is headquartered in Espoo, Finland, with an R&D
center in France and subsidiaries in UK and Sweden.
Combining
Amplidiag and Novodiag solutions, Mobidiag offers a comprehensive line
of products for fast, reliable and cost-efficient diagnostics for
infectious diseases and antibiotic resistances. Mobidiag is able to
cover all laboratories requirements no matter their size, throughput and
centralized/ decentralized organization.
To learn more, visit www.mobidiag.com
About Ginolis Ltd.
Ginolis specializes in providing
high-quality automation, liquid handling and quality control solutions
for the production and processing of healthcare consumables. The company
is privately owned and headquartered in Oulu, Finland, with sites in
Uppsala, Sweden, San Diego, USA and Suzhou, China.
To learn more,
visit Ginolis.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20180304005019/en/
Contact:
Mobidiag Ltd
Dorothee Allard, +33 1 55 25 17 13
marketing@mobidiag.com
or
Ginolis
Teijo
Fabritius, +358 40 565 1782
CEO
teijo.fabritius@ginolis.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NY-HCLTECH26.4.2024 22:07:31 CEST | Press release
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY
KINAXIS-INC.26.4.2024 18:04:28 CEST | Press release
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions
VERTEX-PHARMA26.4.2024 17:44:28 CEST | Press release
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
SUZANO-S.A.26.4.2024 17:23:27 CEST | Press release
Suzano 2023 annual report on Form 20-F
MA-TAKEDA-PHARMACEUTICAL26.4.2024 14:31:34 CEST | Press release
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom